Europe Custom Antibody Market Growth and Analysis by 2028

The custom antibody market in Europe is expected to grow from US$ 102.5 million in 2021 to US$ 213.7 million by 2028; it is estimated to grow at a CAGR of 11.1% from 2021 to 2028. Biotechnology companies have been prominently focusing on collaborations, partnerships, acquisitions, and financial aids or funding for making progress in the markets they serve. Moreover, the COVID-19 pandemic has served opportunities to players to make some important strategic decisions. Following are a few instances of market consolidations that has leveraged growth of custom antibodies market. In January 2021, Morphic Therapeutic, a biotechnology company, collaborated with Janssen Pharmaceutical, Inc., a part of Johnson & Johnson Private Limited, to develop novel antibodies against third integrin target proteins (a family of ubiquitous receptors). Moreover, in July 2020, Cancer Research UK collaborated with Abcam, a life science reagents and tools developer, for the development of custom antibodies to enhance of cancer research and commercialize novel therapies. In January 2020, Abcam acquired Applied StemCell’s gene editing platform and oncology product portfolio, with an aim to strengthen its validation initiative for antibody quality control.

Countries in the European regions were profoundly affected due to the COVID-19 pandemic. For instance, countries such as Italy, Spain, and France have reported the highest number of positive cases and have registered the maximum number of deaths. Several companies have experienced severe losses in the last quarter of 2019; they have also negatively influenced the first and second quarters of 2020. Hence, the impact of COVID 19 on the European market was immediate and drastic. The custom antibody supply chain, which is already logistically complicated, has to face new challenges. The custom antibody market has also witnessed some shortfall at the beginning of the COVID 19 crisis due to disruption in supply chain and demand due to lockdown announced by most European countries. This result may last till the end of 2020 as most of the market players in Europe yet to adopt the novel diagnostic tests for COVID 19. However, in the extended period, the requirement for custom antibodies is expected to increase due to supportive government initiatives. For instance, in May 2020, ProteoGenix launched the first Human Immune COVID-19 library for the fast development of potent antibodies against SARS-CoV-2. Hence, the European custom antibody market will likely show significant growth prospects during this pandemic and forecasted year. Therefore, the preference for adopting custom antibody provides a favorable environment for the growth of the Europe custom antibody market during the forecast period.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the custom antibody market. The Europe Custom antibody market is expected to grow at a good CAGR during the forecast period.

Europe Custom Antibody Market Segmentation    

By Service

• Antibody Development
• Antibody Production and Purification
• Antibody Fragmentation and Labelling

By Type

• Monoclonal Antibodies
• Polyclonal Antibodies
• Other Custom Antibodies

By Source

• Mice
• Rabbits
• Others

By Research Area

• Oncology
• Immunology
• Stem Cells
• Infectious Diseases
• Neurobiology
• Cardiovascular Diseases
• Others

By End User

• Pharmaceutical and Biotechnology Companies
• Academic and Research Institutes
• Contract Research Organizations 

By Country

• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe

Companies Mentioned

• Thermo Fisher Scientific Inc.
• Bio-Rad Laboratories Inc.
• Merck KGAA
• Abcam
• Genscript
• Agilent Technologies, Inc.
• Cell Signaling Technology, Inc.

Europe Custom Antibody Report Scope